Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Common Equity (2016 - 2025)

Historic Common Equity for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $4.1 billion.

  • BeOne Medicines' Common Equity rose 2017.57% to $4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 2017.57%. This contributed to the annual value of $3.3 billion for FY2024, which is 579.83% down from last year.
  • BeOne Medicines' Common Equity amounted to $4.1 billion in Q3 2025, which was up 2017.57% from $3.8 billion recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Common Equity ranged from a high of $6.1 billion in Q4 2021 and a low of $3.3 billion during Q4 2024
  • In the last 5 years, BeOne Medicines' Common Equity had a median value of $3.8 billion in 2025 and averaged $4.1 billion.
  • As far as peak fluctuations go, BeOne Medicines' Common Equity soared by 5849.52% in 2021, and later tumbled by 2852.33% in 2022.
  • Over the past 5 years, BeOne Medicines' Common Equity (Quarter) stood at $6.1 billion in 2021, then fell by 28.52% to $4.4 billion in 2022, then fell by 19.3% to $3.5 billion in 2023, then dropped by 5.8% to $3.3 billion in 2024, then rose by 23.92% to $4.1 billion in 2025.
  • Its Common Equity was $4.1 billion in Q3 2025, compared to $3.8 billion in Q2 2025 and $3.5 billion in Q1 2025.